Skip to main content

Table 4 Percentage of positive CD31 staining in tumor section

From: A novel engineered VEGF blocker with an excellent pharmacokinetic profile and robust anti-tumor activity

Group

% of CD31 in Colo-205

% of CD31 in A549

PBS

6.2 (+/- 2.1)

7.1 (+/-3.2)

Doxorubicin, 3 mg/kg

6.8 (+/- 3.6)

not done

HB-002.1, 5 mg/kg

1.9 (+/- 0.9)

0.7 (+/- 0.2)

Bevacizumab, 20 mg/kg

not done

3.9 (+/- 2.9)

  1. Note: Average (+/- SEM) from 3 samples in each group is shown.
Back to article page

BMC Cancer

ISSN: 1471-2407

Contact us